Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab in Patients with Relapsed Follicular, Indolent, or Mantle Cell Lymphomas – 8-Year Follow-up Results of the Randomized Phase III Study NHL 2-2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany)
Mathias Rummel(Universitätsklinikum Gießen und Marburg), Wolfram Brugger(University of Freiburg), Martina Stauch, Andrea Heider(Klinikum Leverkusen), Christina Balser(Philipps University of Marburg), Frank Kauff(Justus-Liebig-Universität Gießen), Ulrich Kaiser(University of Applied Sciences Landshut), Axel Hinke, Wolfgang Blau(Universitätsklinikum Gießen und Marburg), Jürgen Barth(Justus-Liebig-Universität Gießen), Eckhart Weidmann(Krankenhaus Nordwest), Manfred Welslau(Klinikum Aschaffenburg), Alexander Burchardt(Johannes Gutenberg University Mainz), Christoph Losem, Hans Peter Böck
Cited by 5
Related Papers
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
|European Journal of Cancer|2011|615
The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML
|Blood|2010|485
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
|New England Journal of Medicine|2010|425